Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.
作者： A Lerner , R Gonin , G D Steele , R J Mayer
DOI: 10.1200/JCO.1992.10.4.536
关键词:
摘要: PURPOSEA phase II study of etoposide, doxorubicin, and cisplatin (EAP) therapy in patients with advanced gastric carcinoma was performed an attempt to confirm encouraging results reported by German investigators using identical EAP regimen.PATIENTS AND METHODSThirty-six consecutive, previously untreated surgically unresectable, measurable were treated every 28 days etoposide (120 mg/m2, 4, 5, 6), doxorubicin (20 1 7), (40 2 8). A total 108 courses treatment given.RESULTSTherapy associated myelosuppression (median granulocyte nadir, 239/microL; median platelet 81,000/microL), which reached its maximum 14 after the start necessitated hospitalization 24 (22%) courses. Four 36 (11%) died treatment-related toxicity: three from sepsis one hemorrhage. Objective responses observed 12 (33%) patients; (8%) p...
sci-hub.se 参考文章(24)
P Preusser, H Wilke, W Achterrath, U Fink, L Lenaz, A Heinicke, J Meyer, H J Meyer, H Buente, Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. Journal of Clinical Oncology. ,vol. 7, pp. 1310- 1317 ,(1989) , 10.1200/JCO.1989.7.9.1310
C G Moertel, J Rubin, M J O'Connell, A J Schutt, H S Wieand, A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. Journal of Clinical Oncology. ,vol. 4, pp. 1053- 1057 ,(1986) , 10.1200/JCO.1986.4.7.1053
D Kelsen, O T Atiq, L Saltz, D Niedzwiecki, D Ginn, D Chapman, R Heelan, C Lightdale, V Vinciguerra, M Brennan, FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. Journal of Clinical Oncology. ,vol. 10, pp. 541- 548 ,(1992) , 10.1200/JCO.1992.10.4.541
J A Wils, H O Klein, D J Wagener, H Bleiberg, H Reis, F Korsten, T Conroy, M Fickers, S Leyvraz, M Buyse, Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: A step ahead in the treatment of advanced gastric cancer: a trial of the European organization for research and treatment of cancer gastrointestinal tract cooperative group Journal of Clinical Oncology. ,vol. 9, pp. 827- 831 ,(1991) , 10.1200/JCO.1991.9.5.827
J Powell, CC McConkey, Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. British Journal of Cancer. ,vol. 62, pp. 440- 443 ,(1990) , 10.1038/BJC.1990.314
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Blake Cady, Gastric Adenocarcinoma Archives of Surgery. ,vol. 124, pp. 303- 308 ,(1989) , 10.1001/ARCHSURG.1989.01410030049009
Joseph A. Sparano, Edward L. Schwartz, Kathryn M. Salva, Michael F. Pizzillo, Scott Wadler, Peter H. Wiernik, Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. American Journal of Clinical Oncology. ,vol. 13, pp. 374- 378 ,(1990) , 10.1097/00000421-199010000-00002
Manuel Moutinho Ribeiro, J. Alexandre Sarmento, M. A. Sobrinho Simões, Joaquim Bastos, Prognostic significance of Lauren and Ming classifications and other pathologic parameters in gastric carcinoma Cancer. ,vol. 47, pp. 780- 784 ,(1981) , 10.1002/1097-0142(19810215)47:4<780::AID-CNCR2820470424>3.0.CO;2-G